Ensuring Access to Essential Drugs Act

HR1922, titled the Ensuring Access to Essential Drugs Act, was introduced in the House of Representatives on March 6, 2025. It has since been referred to the Committee on Energy and Commerce and the Committee on Ways and Means. This bill seeks to amend the Social Security Act to exempt certain orally administered, brand-name drugs from the Medicare Part D Manufacturer Discount Program, specifically those reclassified as noninnovator multiple source drugs under the Medicaid drug rebate program by the Centers for Medicare & Medicaid Services. The mechanism of this bill is regulatory relief rather than direct funding. By exempting specific drugs from the Medicare Part D Manufacturer Discount Program, pharmaceutical companies producing these drugs would no longer be required to provide discounts to beneficiaries who have incurred costs above the annual deductible. This would effectively increase the net revenue for manufacturers of these particular drugs by reducing their rebate obligations. However, the bill does not specify which drugs would qualify, nor does it provide an estimated financial impact. Potential beneficiaries of this regulatory change would be pharmaceutical companies that produce orally administered brand-name drugs that meet the specific reclassification criteria under the Medicaid drug rebate program. Companies like Pfizer ($PFE), Johnson & Johnson ($JNJ), Merck & Co. ($MRK), Eli Lilly and Company ($LLY), Amgen Inc. ($AMGN), Gilead Sciences ($GILD), Bristol-Myers Squibb Company ($BMY), and AbbVie Inc. ($ABBV) are major players in the pharmaceutical sector and could potentially benefit if they have qualifying drugs. However, without specific drug identification, the direct impact on any single company remains speculative. The bill's early stage means no immediate market reaction is observed or expected. Currently, the bill is in the very early stages of the legislative process, having only been introduced and referred to committees. There have been no further actions since its introduction on March 6, 2025. For the bill to advance, it would need to be considered and passed by both committees, then by the full House, and subsequently by the Senate, before being signed into law by the President. This process typically takes a significant amount of time, and many bills introduced at this stage do not become law.